Advertisement

Statin use increased new-onset diabetes in hypercholesterolemic individuals: Data from the Korean National Health Insurance Service-National Health Screening Cohort database (NHIS-HEALS)

  • Author Footnotes
    1 These authors are co-first authors and equally contributed to this work.
    Ye-Seul Kim
    Footnotes
    1 These authors are co-first authors and equally contributed to this work.
    Affiliations
    Department of Family Medicine, Chungbuk National University Hospital, Cheongju, Republic of Korea
    Search for articles by this author
  • Author Footnotes
    1 These authors are co-first authors and equally contributed to this work.
    Ye-Eun Han
    Footnotes
    1 These authors are co-first authors and equally contributed to this work.
    Affiliations
    Department of Information & Statistics, Chungbuk National University, Cheongju, Republic of Korea
    Search for articles by this author
  • Eun-A Choi
    Affiliations
    Department of Information & Statistics, Chungbuk National University, Cheongju, Republic of Korea
    Search for articles by this author
  • Na-Young You
    Affiliations
    Department of Information & Statistics, Chungbuk National University, Cheongju, Republic of Korea
    Search for articles by this author
  • Jae-woo Lee
    Affiliations
    Department of Family Medicine, Chungbuk National University Hospital, Cheongju, Republic of Korea
    Search for articles by this author
  • Hyo-Sun You
    Affiliations
    Department of Family Medicine, Chungbuk National University Hospital, Cheongju, Republic of Korea
    Search for articles by this author
  • Yonghwan Kim
    Affiliations
    Department of Family Medicine, Chungbuk National University Hospital, Cheongju, Republic of Korea
    Search for articles by this author
  • Author Footnotes
    2 These co-corresponding authors equally contributed to this work.
    Joungyoun Kim
    Correspondence
    Corresponding author at: Department of Information & Statistics, Chungbuk National University, 1 Chungdae-ro, Seowon-gu Cheongju, Chungbuk, 28644 Republic of Korea.
    Footnotes
    2 These co-corresponding authors equally contributed to this work.
    Affiliations
    Department of Information & Statistics, Chungbuk National University, Cheongju, Republic of Korea
    Search for articles by this author
  • Author Footnotes
    2 These co-corresponding authors equally contributed to this work.
    Hee-Taik Kang
    Correspondence
    Corresponding author at: Department of Family Medicine, Chungbuk National University Hospital, Department of Family Medicine, Chungbuk National University College of Medicine, 1 Chungdae-ro, Seowon-gu, Cheongju, Chungcheongbuk-do, 28644, Republic of Korea.
    Footnotes
    2 These co-corresponding authors equally contributed to this work.
    Affiliations
    Department of Family Medicine, Chungbuk National University Hospital, Cheongju, Republic of Korea

    Department of Family Medicine, Chungbuk National University College of Medicine, Cheongju, Chungbuk, Republic of Korea
    Search for articles by this author
  • Author Footnotes
    1 These authors are co-first authors and equally contributed to this work.
    2 These co-corresponding authors equally contributed to this work.
Published:September 20, 2019DOI:https://doi.org/10.1016/j.pcd.2019.08.005

      Highlights

      • This study shows that there were risks for new-onset diabetes mellitus (NODM) in statin users.
      • There was higher risk for NODM in statin low-users than high-users.
      • There was a possibility of dose and type differences in statin’s diabetogenic effects.

      Abstract

      Aim

      We investigated the association between statin use and new-onset diabetes (NODM) in Korean adults with hypercholesterolemia.

      Methods

      This study performed based on data from the National Health Insurance Service-National Health Screening Cohort for the years from 2002 to 2015. Statin users classified as high- or low- users according to medication possession ratio. Statin non-users consisted of hypercholesterolemic participants who never used statin over the entire follow-up period. 21,469 participants (10,880 statin users, 10,589 statin non-users) with a median follow-up period of 12.5 years were included. We estimated the NODM risk based on the survival analyses. In particular, to adjust for confounding effects, we considered Cox proportional hazards regression models over three stages.

      Results

      Compared to non-users, statin users had a significantly higher risk for NODM. The fully adjusted hazard ratios (aHRs) (95% confidential intervals [95% CIs]) of statin users for NODM were 1.43 (1.31–1.57) in men, and 1.86 (1.66–2.10) in women, respectively after adjusted confounding factors including age and lifestyle factors. Compared to high-users, aHRs (95% CIs) of low-users for NODM were 1.16 (1.03–1.30) and 1.28 (1.16–1.43) in men and women, respectively.

      Conclusions

      In hypercholesterolemic patients, statin users have a higher risk of NODM than non-users.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Primary Care Diabetes
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Low W.Y.
        • Lee Y.K.
        • Samy A.L.
        Non-communicable diseases in the Asia-Pacific region: prevalence, risk factors and community-based prevention.
        Int. J. Occup. Med. Environ. Health. 2015; : 1-7
        • Cho N.H.
        • Shaw J.E.
        • Karuranga S.
        • et al.
        IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045.
        Diabetes Res. Clin. Pract. 2018; 138: 271-281
      1. The Ministry of Health and Welfare and the Korean Centers for Disease Control and Prevention, Current Status and Issues of Chronic Disease.
        2018 ((Available from : file:)
        • Zhang P.
        • Zhang X.
        • Brown J.
        • et al.
        Global healthcare expenditure on diabetes for 2010 and 2030.
        Diabetes Res. Clin. Pract. 2010; 87: 293-301
        • Hodgson T.A.
        • Cohen A.J.
        Medical care expenditures for diabetes, its chronic complications, and its comorbidities.
        Prev. Med. 1999; 29: 173-186
        • Stancu C.
        • Sima A.
        Statins: mechanism of action and effects.
        J. Cell. Mol. Med. 2001; 5: 378-387
        • Stone N.J.
        • Robinson J.G.
        • Lichtenstein A.H.
        • et al.
        2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
        J. Am. Coll. Cardiol. 2014; 63: 2889-2934
        • Preiss D.
        • Seshasai S.R.K.
        • Welsh P.
        • et al.
        Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.
        JAMA. 2011; 305: 2556-2564
        • Sattar N.
        • Preiss D.
        • Murray H.M.
        • et al.
        Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.
        Lancet. 2010; 375: 735-742
        • Corrao G.
        • Compagnoni M.M.
        • Rea F.
        • Merlino L.
        • et al.
        Clinical significance of diabetes likely induced by statins: evidence from a large population-based cohort.
        Diabetes Res. Clin. Pract. 2017; 133: 60-68
        • Rajpathak S.N.
        • Kumbhani D.J.
        • Crandall J.
        • et al.
        Statin therapy and risk of developing type 2 diabetes: a meta-analysis.
        Diabetes Care. 2009; 32: 1924-1929
        • U. Food
        • D. Administration
        FDA Drug Safety Communication: Important Safety Label Changes to Cholesterol-lowering Statin Drugs.
        US Food and Drug Administration, Rockville, MD2012 (Available from https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-important-safety-label-changes-cholesterol-lowering-statin-drugs)
        • Kozma C.M.
        • Dickson M.
        • Phillips A.L.
        • Meletiche D.M.
        Medication possession ratio: implications of using fixed and variable observation periods in assessing adherence with disease-modifying drugs in patients with multiple sclerosis.
        Patient Prefer. Adherence. 2013; 7: 509
        • He Y.
        • Li X.
        • Gasevic D.
        • et al.
        Statins and multiple noncardiovascular outcomes: umbrella review of meta-analyses of observational studies and randomized controlled trials.
        Ann. Intern. Med. 2018; 169: 543-553
        • Wolozin B.
        • Kellman W.
        • Ruosseau P.
        • et al.
        Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.
        Arch. Neurol. 2000; 57: 1439-1443
        • Tonelli M.
        • Moyé L.
        • Sacks F.M.
        • et al.
        Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease.
        J. Am. Soc. Nephrol. 2003; 14: 1605-1613
        • Erqou S.
        • Lee C.C.
        • Adler A.I.
        Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis.
        Diabetologia. 2014; 57: 2444-2452
        • Ridker P.M.
        • Pradhan A.
        • MacFadyen J.G.
        • Libby P.
        • Glynn R.J.
        Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial.
        Lancet. 2012; 380: 565-571
        • Freeman D.J.
        • Norrie J.
        • Sattar N.
        • et al.
        Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study.
        Circulation. 2001; 103: 357-362
        • Keech A.
        • Colquhoun D.
        • Best J.
        • et al.
        Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial.
        Diabetes Care. 2003; 26: 2713-2721
        • Navarese E.P.
        • Buffon A.
        • Andreotti F.
        • et al.
        Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus.
        Am. J. Cardiol. 2013; 111: 1123-1130
        • Ma T.
        • Tien L.
        • Fang C.L.
        • Liou Y.S.
        • Jong G.P.
        Statins and new-onset diabetes: a retrospective longitudinal cohort study.
        Clin. Ther. 2012; 34: 1977-1983
        • Kim S.H.
        Statin and the risk of new-onset diabetes mellitus.
        J. Korean Med. Assoc. 2017; 60: 901-911
        • Cho Y.
        • Choe E.
        • Lee Yh.
        • et al.
        Risk of diabetes in patients treated with HMG-CoA reductase inhibitors.
        Metab.-Clin. Exp. 2015; 64: 482-488
        • Rha S.W.
        • Choi B.G.
        • Seo H.S.
        • et al.
        Impact of statin use on development of new-onset diabetes mellitus in Asian population.
        Am. J. Cardiol. 2016; 117: 382-387
        • Lee J.
        • Noh Y.
        • Shin S.
        • et al.
        Impact of statins on risk of new onset diabetes mellitus: a population-based cohort study using the Korean National Health Insurance claims database.
        Ther. Clin. Risk Manage. 2016; 12: 1533
        • Brault M.
        • Ray J.
        • Gomez Y.-H.
        • Mantzoros C.S.
        • Daskalopoulou S.S.
        Statin treatment and new-onset diabetes: a review of proposed mechanisms.
        Metabo.-Clin. Exp. 2014; 63: 735-745
        • Zhou J.
        • Li W.
        • Xie Q.
        • Hou Y.
        • et al.
        Effects of simvastatin on glucose metabolism in mouse MIN6 cells.
        J. Diabetes Res. 2014; 2014https://doi.org/10.1155/2014/376570
        • Yada T.
        • Nakata M.
        • Shiraishi T.
        • Kakei M.
        Inhibition by simvastatin, but not pravastatin, of glucose‐induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L‐type Ca2+ channels in rat islet β‐cells.
        Br. J. Pharmacol. 1999; 126: 1205-1213
        • Mabuchi H.
        • Higashikata T.
        • Kawashiri M.
        • et al.
        Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients.
        J. Atheroscler. Thromb. 2005; 12: 111-119
        • Goldstein M.R.
        • Mascitelli L.
        Statin-induced diabetes: perhaps, it’s the tip of the iceberg.
        QJM. 2010; 104: 174-178
        • Kanda M.
        • Satoh K.
        • Ichihara K.
        Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin.
        Biol. Pharm. Bull. 2003; 26: 1681-1684
        • Andrade S.E.
        • Kahler K.H.
        • Frech F.
        • Chan K.A.
        Methods for evaluation of medication adherence and persistence using automated databases.
        Pharmacoepidemiol. Drug Saf. 2006; 15: 565-574
        • Dragomir A.
        • Côté R.
        • White M.
        • Lalonde L.
        • Blais L.
        • Bérard A.
        • Perreault S.
        Relationship between adherence level to statins, clinical issues and health‐care costs in real‐life clinical setting.
        Value Health. 2010; 13: 87-94